Related Experiment Video
Updated: Jul 16, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Self-Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer
Jiaxing Pan1, Yi Lai2, Shunan Zhang2
1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 2000092, China.
Abstract:
The advance of immunotherapy has shifted the paradigm of cancer management in clinics. Nevertheless, a considerable subset of pancreatic ductal adenocarcinoma (PDAC) patients marginally respond to current immunotherapy due to the occurrence of dynamic immune evasion arising from intrinsic and therapeutic stress. In this investigation, the pivotal role of pancreatic cancer-associated fibroblast (CAF)-induced fibrosis and tumor cell-mediated T-cell exhaustion in driving the dynamic immune evasion is identified. Building upon this discovery, the authors herein engineer a novel peptide-drug conjugate (PDC)-based self-adaptive nanoregulator for mitigating dynamic immune evasion of PDAC. The resulting nanoregulator can perform a two-stage morphology transformation from spherical micelle to nanofiber, and subsequently from nanofiber to spherical nanoparticles. Such kind of nanostructure design can facilitate differentialized delivery of CAF inhibitor in the extracellular matrix for intervening CAF-mediated tumor fibrosis, and indoleamine 2,3-dioxygenase 1 inhibitor to tumor cells for relieving IDO1-kynurenine axis-induced T-cell exhaustion. Antitumor study with the self-adaptive nanoregulator elicited persistent antitumor immunity and remarkable antitumor performance in both Panc02 and KPC tumor models in vivo. Taken together, the PDC-based self-adaptive nanoregulator may provide a novel avenue for enhanced PDAC immunotherapy.
Insights
This study introduces a novel nanoregulator to overcome immunotherapy resistance in pancreatic cancer. The nanoregulator targets cancer-associated fibroblasts and T-cell exhaustion, enhancing anti-tumor immunity.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Immunotherapy has revolutionized cancer treatment, but pancreatic ductal adenocarcinoma (PDAC) patients often show limited response due to immune evasion.
- Dynamic immune evasion in PDAC stems from cancer-associated fibroblast (CAF)-induced fibrosis and T-cell exhaustion.
- Therapeutic stress can exacerbate immune evasion in PDAC.
Purpose of the Study:
- To engineer a novel peptide-drug conjugate (PDC)-based self-adaptive nanoregulator to mitigate immune evasion in PDAC.
- To address CAF-mediated fibrosis and T-cell exhaustion contributing to immunotherapy resistance.
Main Methods:
- Development of a nanoregulator with a two-stage morphology transformation (micelle to nanofiber to nanoparticle).
- Differentialized delivery of a CAF inhibitor to the extracellular matrix and an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor to tumor cells.
- In vivo antitumor studies using Panc02 and KPC tumor models.
Main Results:
- The nanoregulator successfully delivered inhibitors to target sites, reducing fibrosis and T-cell exhaustion.
- Demonstrated persistent antitumor immunity and significant antitumor performance in preclinical models.
- The self-adaptive nanoregulator effectively overcame dynamic immune evasion.
Conclusions:
- PDC-based self-adaptive nanoregulators offer a promising strategy for enhancing PDAC immunotherapy.
- This approach may overcome resistance mechanisms in pancreatic cancer.
- Further development could lead to improved clinical outcomes for PDAC patients.
